, Tracking Stock Market Picks
Enter Symbol:
China Biologic Products Inc (CBPO) [hlAlert]

up 913.60 %

China Biologic Products Inc (CBPO) rated Buy with price target $20 by Brean Murray

Posted on: Thursday,  May 13, 2010  8:25 AM ET by Brean Murray

Brean Murray rated Buy China Biologic Products Inc (NASDAQ: CBPO) on 05/13/2010. Previously Brean Murray rated Buy China Biologic Products Inc (NASDAQ: CBPO)
on 12/14/2009., when the stock price was $9.85. Since then, China Biologic Products Inc has gained 913.60% as of 10/08/2015's recent price of $99.84.
If you would have followed the previous Brean Murray's recommendation on CBPO, you would have gained 913.6% of your investment in 2124 days.

China Biologic Products, Inc. is a biopharmaceutical company and through its Chinese subsidiaries, Shandong Taibang and Qianfeng, and Huitian, the Company is engaged in the research, development and manufacturing of plasma-based pharmaceutical products in China. It sells human albumin, which represented approximately 49.7% during the year ended December 31, 2009. Human albumin is principally used to increase blood volume while immunoglobulin is used for certain disease preventions and cures. The Company sells human albumin 20%/10ml, 20%/25ml, 20%/50ml, 10%/10ml, 10%/25ml, 10%/50ml and 25%/50ml. It sells the products to customers in the People Republic of China (PRC), mainly hospitals and inoculation centers. In June 2009, it purchased 35% interest in Xi'an Huitian Blood Products Co., Ltd. On December 21, 2009, the Company established Logic Management and Consulting (China) Co., Ltd.

Our equity research department is focused on fundamental analysis across the universe of over 200 small/mid cap stocks in our five target sectors. We are committed to providing proprietary action-oriented research to our institutional clients. Small cap growth focus. Our primary area of concentration is growth stocks with market capitalization of $200 million to $5 billion. Global perspective. We are covering U.S. listed stocks for companies domiciled in the U.S., China, Europe and Latin America, with our biggest concentration in the US and China. We were one of the first banks to aggressively expand our research to China and we believe we created one of the premier research franchises in small cap, U.S. listed Chinese companies to complement our strong domestic coverage. Disciplined stock selection. Our research analysts are focused on performing extensive bottoms up due diligence on companies under our coverage by leveraging their industry and management contacts. By combining our bottoms up work with our sector views we seek to generate a consistent flow of high conviction ideas for our clients. Diversified coverage. Our areas of expertise include technology, consumer, healthcare, resources and China small cap. We provide our clients with company-specific as well as sector-specific research across our target sectors.
Stock Market Advice
Date/Time (ET)SymbolRatingTermPrice (*)Target
5/13/2010 8:25 AM Buy
13.90 20.00
as of 12/31/2010
1 Week up  2.15 %
1 Month up  38.48 %
3 Months up  63.15 %
1 YTD up  33.44 %
Previous Recommendations
Date/Time (ET)SymbolRatingTermPrice (*)Target
3/26/2010 8:25 AM Buy
11.45 19.00
12/14/2009 9:25 AM Buy
9.85 18.00

(*) Stock Price at the time of the recommendation.
RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy